Technical Analysis for ONCO - Onconetix, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 0.11 | 0.36% | 0.00 |
ONCO closed up 0.36 percent on Wednesday, May 15, 2024, on 29 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.
Earnings due: May 30
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Resistance | Bearish | 0.00% | |
Shooting Star Candlestick | Bearish | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Doji - Bearish? | Reversal | 0.00% | |
Spinning Top | Other | 0.36% | |
Inside Day | Range Contraction | 0.36% | |
Gapped Down | Weakness | 0.36% | |
Lower Bollinger Band Touch | Weakness | 0.36% | |
Inside Day | Range Contraction | -1.59% | |
Lower Bollinger Band Touch | Weakness | -1.59% |
Alert | Time |
---|---|
Rose Above Previous Day's High | about 20 hours ago |
20 DMA Resistance | about 20 hours ago |
10 DMA Resistance | about 20 hours ago |
Up 5% | about 20 hours ago |
Up 3% | about 20 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/30/2024
Onconetix, Inc. (formerly Blue Water Biotech, Inc. (BWV)) is a commercial stage biotechnology company focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The Company currently has Entadfi®, an FDA approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix®, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology FDA Disorders Prostate Cancer Urology Benign Prostatic Hyperplasia Bph Men's Health Prostate Treatment Of Benign Prostatic Hyperplasia
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology FDA Disorders Prostate Cancer Urology Benign Prostatic Hyperplasia Bph Men's Health Prostate Treatment Of Benign Prostatic Hyperplasia
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 1.58 |
52 Week Low | 0.1001 |
Average Volume | 326,157 |
200-Day Moving Average | 0.35 |
50-Day Moving Average | 0.14 |
20-Day Moving Average | 0.12 |
10-Day Moving Average | 0.11 |
Average True Range | 0.01 |
RSI (14) | 38.27 |
ADX | 12.28 |
+DI | 18.46 |
-DI | 19.56 |
Chandelier Exit (Long, 3 ATRs) | 0.10 |
Chandelier Exit (Short, 3 ATRs) | 0.14 |
Upper Bollinger Bands | 0.13 |
Lower Bollinger Band | 0.11 |
Percent B (%b) | 0.26 |
BandWidth | 20.78 |
MACD Line | -0.01 |
MACD Signal Line | -0.01 |
MACD Histogram | 0.001 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.12 | ||||
Resistance 3 (R3) | 0.12 | 0.12 | 0.12 | ||
Resistance 2 (R2) | 0.12 | 0.12 | 0.12 | 0.12 | |
Resistance 1 (R1) | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 |
Pivot Point | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 |
Support 1 (S1) | 0.11 | 0.11 | 0.11 | 0.11 | 0.10 |
Support 2 (S2) | 0.11 | 0.11 | 0.11 | 0.10 | |
Support 3 (S3) | 0.10 | 0.11 | 0.10 | ||
Support 4 (S4) | 0.10 |